Concepedia

Author

Jan Balzarini

Rega Institute for Medical Research

Also Known As

Balzarini J, Balzarini, J., Balzarini, Jan, J BALZARINI, J Balzarini, J. BALZARINI, J. Balzarini, J. M. BALZARINI, JAN BALZARINI, Jan BALZARINI

946

Publications

13.9K

Citations

59

H-Index

135

Concepts

All Affiliations

Rega Institute for Medical ResearchKU LeuvenUniversity of SaskatchewanCardiff UniversityNational Institutes of Health
JB

About

Jan Balzarini is an author at Rega Institute for Medical Research specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

40

118

4.9K

2

Natural Sciences

30

95

3.5K

3

Engineering

18

31

1.2K

4

Health Sciences

2

2

44

5

Public Health

1

1

61

Jan Balzarini

×

277

Publications

11.8K

Citations

57

H-Index

YearCitations

1,2,3-Triazole-[2,5-Bis-O-(tert-butyldimethylsilyl)-.beta.-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) (TSAO) Analogs: Synthesis and Anti-HIV-1 Activity

Rosa Álvarez, Sonsoles Velázquez, Ana San‐Félix,

Journal of Medicinal Chemistry

1994

746

Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs

Jan Wijnholds, Carla A.A.M. Mol, Liesbeth van Deemter,

Proceedings of the National Academy of Sciences

2000

472

Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives

Deepika Sharma, Balasubramanian Narasimhan, Pradeep Kumar,

European Journal of Medicinal Chemistry

2008

243

Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14

Festo Damian, N. M. Blaton, Lieve Naesens,

European Journal of Pharmaceutical Sciences

2000

229

A Conformational and Structure−Activity Relationship Study of Cytotoxic 3,5-Bis(arylidene)-4-piperidones and Related <i>N</i>-Acryloyl Analogues

Jonathan R. Dimmock, Maniyan P. Padmanilayam, R.N. Puthucode,

Journal of Medicinal Chemistry

2001

212

Can positron emission tomography with [<sup>18</sup>F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

Karoline Spaepen, Sigrid Stroobants, Patrick Dupont,

British Journal of Haematology

2001

169

Synthesis of Acyclo-<i>C</i>-nucleosides in the Imidazo[1,2-<i>a</i>]pyridine and Pyrimidine Series as Antiviral Agents

Alain Gueiffier, Mohammed Lhassani, Ahmed Elhakmaoui,

Journal of Medicinal Chemistry

1996

161

Successful Treatment of Progressive Mucocutaneous Infection Due to Acyclovirand Foscarnet-Resistant Herpes Simplex Virus with (S)-1-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine (HPMPC)

Robert Snoeck, Graciela Andreï, M. Gérard,

Clinical Infectious Diseases

1994

158

Synthesis and Biological Evaluation of 2- and 3-Aminobenzo[<i>b</i>]thiophene Derivatives as Antimitotic Agents and Inhibitors of Tubulin Polymerization

Romeo Romagnoli, Pier Giovanni Baraldi, María Dora Carriòn,

Journal of Medicinal Chemistry

2007

141

3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2', 5'-bis-O-(tert-butyldimethylsilyl)-.beta.-D-xylo- and -ribofuranose]-3'-spiro-5''-[4''-amino-1'', 2''-oxathiole 2'', 2''-dioxide] (TSAO) pyrimidine nucleosides

Marı́a-José Camarasa, María‐Jesús Pérez‐Pérez, Ana San‐Félix,

Journal of Medicinal Chemistry

1992

127

Page 1